• Branislav Bezak, Peter Snopek, Lubomira Tothova, Nikola Jajcay, Viliam Mojto, Stefan Farsky, Karin Gmitterova, Marek Krivosik, Simona Stankova, Olga Duranikova, Marta Kollarova, Katarina Petrikova, and Allan Bohm.
• Bratisl Med J. 2023 Jan 1; 124 (5): 368372368-372.

ObjectivesPurpose of this study was to evaluate properties of apelin, a peptide detectable in peripheral blood, for atrial fibrillation (AF) detection in a diverse population of patients covering a broad spectrum from healthy to polymorbid patients.BackgroundAF is the most common cardiac arrhythmia with constantly increasing incidence and prevalence. Currently available diagnostic tools do not provide sufficient detection rate. Large proportion of patients with AF remains undiagnosed and the possibility of screening at-risk groups would be significantly beneficial.MethodsWe designed this study as a multi-centre retrospective study. Study population included 183 patients. 64 in non-AF and 119 in AF group.ResultsApelin plasma concentration was significantly lower in AF group compared to non-AF group (p < 0.001). Receiver operating characteristic analysis of apelin as a predictor of AF scored area under the curve of 0.79, sensitivity = 0.941 and specificity = 0.578. Multivariate analysis using logistic regression adjusted for age, BMI, apelin, dilated LV, dilated LA, arterial hypertension, and gender showed only apelin and age to be statistically significant contributors for AF.ConclusionApelin might be a promising biomarker for detecting AF in our study population. These results suggest promising potential of apelin as a screening biomarker for AF (Tab. 2, Fig. 1, Ref. 46). Text in PDF www.elis.sk Keywords: biomarker, apelin, arrhythmia, atrial fibrillation.

15 keywords...

hide…